" ]) A- U4 i" u& E6 K
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究: & j. \2 o/ E4 C! S+ nEverolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.3 s" r% I# g+ e: p http://www.ncbi.nlm.nih.gov/pubmed/22968184/ |* A: L& l* s